Qingdao Xnoba Biological Technology

Qingdao Xnoba Biological Technology is a Chinese biotechnology company focused on the development of next-generation gene editing tools and therapeutic applications. Founded in 2021 by scientists from the Chinese Academy of Sciences, the company specializes in proprietary CRISPR/Cas systems and high-precision base editing technologies. Xnoba's platform aims to address the limitations of existing genomic medicines by improving delivery efficiency and minimizing off-target effects. The company is currently advancing a pipeline of pre-clinical programs targeting various genetic and rare diseases. With a strong foundation in protein engineering, Xnoba is dedicated to translating cutting-edge genomic research into curative clinical solutions.